title: Targeting the "Rising DAMP" during a Francisella tularensis Infection.
abstract: Antibiotic efficacy is greatly enhanced the earlier it is administered following infection with a bacterial pathogen. However, in a clinical setting antibiotic treatment usually commences following the onset of symptoms, which in some cases (e.g., biothreat agents) may be too late. In a BALB/c murine intranasal model of infection forFrancisella tularensisSCHU S4 infection, we demonstrate during a time course experiment that proinflammatory cytokines and the damage-associated molecular pattern HMGB1 were not significantly elevated above naive levels in tissue or sera until 72 h postinfection. HMGB1 was identified as a potential therapeutic target that could extend the window of opportunity for the treatment of tularemia with antibiotics. Antibodies to HMGB1 were administered in conjunction with a delayed/suboptimal levofloxacin treatment ofF. tularensisWe found in the intranasal model of infection that treatment with anti-HMGB1 antibody, compared to an isotype IgY control antibody, conferred a significant survival benefit and decreased bacterial loads in the spleen and liver but not the lung (primary loci of infection) 4 days into infection. We also observed an increase in the production of gamma interferon in all tested organs. These data demonstrate that treatment with anti-HMGB1 antibody is beneficial in enhancing the effectiveness of current antibiotics in treating tularemia. Strategies of this type, involving antibiotics in combination with immunomodulatory drugs, are likely to be essential for the development of a postexposure therapeutic for intracellular pathogens.
authors.affiliation: Biomedical Sciences, Dstl Porton Down, Salisbury, United Kingdom rvdelia@dstl.gov.uk.
authors.forename: Riccardo V
authors.initials: RV
authors.lastname: D'Elia
authors.affiliation: Biomedical Sciences, Dstl Porton Down, Salisbury, United Kingdom.
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Laws
authors.affiliation: Biomedical Sciences, Dstl Porton Down, Salisbury, United Kingdom.
authors.forename: Alun
authors.initials: A
authors.lastname: Carter
authors.affiliation: Biomedical Sciences, Dstl Porton Down, Salisbury, United Kingdom.
authors.forename: Roman
authors.initials: R
authors.lastname: Lukaszewski
authors.affiliation: Biomedical Sciences, Dstl Porton Down, Salisbury, United Kingdom.
authors.forename: Graeme C
authors.initials: GC
authors.lastname: Clark